6,557 research outputs found
A network-based dynamical ranking system for competitive sports
From the viewpoint of networks, a ranking system for players or teams in
sports is equivalent to a centrality measure for sports networks, whereby a
directed link represents the result of a single game. Previously proposed
network-based ranking systems are derived from static networks, i.e.,
aggregation of the results of games over time. However, the score of a player
(or team) fluctuates over time. Defeating a renowned player in the peak
performance is intuitively more rewarding than defeating the same player in
other periods. To account for this factor, we propose a dynamic variant of such
a network-based ranking system and apply it to professional men's tennis data.
We derive a set of linear online update equations for the score of each player.
The proposed ranking system predicts the outcome of the future games with a
higher accuracy than the static counterparts.Comment: 6 figure
How citation boosts promote scientific paradigm shifts and Nobel Prizes
Nobel Prizes are commonly seen to be among the most prestigious achievements
of our times. Based on mining several million citations, we quantitatively
analyze the processes driving paradigm shifts in science. We find that
groundbreaking discoveries of Nobel Prize Laureates and other famous scientists
are not only acknowledged by many citations of their landmark papers.
Surprisingly, they also boost the citation rates of their previous
publications. Given that innovations must outcompete the rich-gets-richer
effect for scientific citations, it turns out that they can make their way only
through citation cascades. A quantitative analysis reveals how and why they
happen. Science appears to behave like a self-organized critical system, in
which citation cascades of all sizes occur, from continuous scientific progress
all the way up to scientific revolutions, which change the way we see our
world. Measuring the "boosting effect" of landmark papers, our analysis reveals
how new ideas and new players can make their way and finally triumph in a world
dominated by established paradigms. The underlying "boost factor" is also
useful to discover scientific breakthroughs and talents much earlier than
through classical citation analysis, which by now has become a widespread
method to measure scientific excellence, influencing scientific careers and the
distribution of research funds. Our findings reveal patterns of collective
social behavior, which are also interesting from an attention economics
perspective. Understanding the origin of scientific authority may therefore
ultimately help to explain, how social influence comes about and why the value
of goods depends so strongly on the attention they attract.Comment: 6 pages, 6 figure
Recommended from our members
Implementation of Additive Manufacturing in the Healthcare Supply Chain for Circular Economy Goals: Paradoxical Tensions and Solutions from an Industry 5.0 Perspective
Data Availability:
The original dataset is available on request.This study addresses the paradoxical tensions that arise during additive manufacturing (AM) implementation for circular economy goals in the healthcare sector. Using the lens of paradox theory, this study identifies four competing priorities that stakeholders may encounter while adopting AM. Focus group discussions among 12 industry experts from the healthcare supply chain were conducted to verify the paradoxes. Semi-structured interviews were then conducted with 10 industry experts to derive the solutions to manage these tensions from an Industry 5.0 perspective to achieve the full benefits of AM. This study expands paradox theory into the AM literature and provides a novel ‘both/and’ perspective (i.e. a pluralistic rather than a dualistic perspective) to look at emerging tensions encountered while implementing AM in the healthcare sector. This perspective will help decision-makers realise that these tensions can be managed over time to turn them into creative, rather than destructive, forces
Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma
AIMS: The decision to consider adjuvant chemotherapy (AC) for non-small cell lung cancer is currently governed by clinical stage. This study aims to assess other routinely collected pathological variables related to metastasis and survival for their ability to predict the efficacy of AC in lung adenocarcinoma. METHODS AND RESULTS: A retrospective single-centre series of 620 resected lung non-mucinous adenocarcinoma cases from 2005-2015 was used. Digital images of all slides were subjected to central review, and data on tumour histopathology, AC treatment and patient survival were compiled. A statistical case matching approach was used to counter selection bias. Several high-risk pathological criteria predict both pathological nodal involvement and early death: positive vascular invasion status (VI+) (HR=2.10 P<0.001), positive visceral pleural invasion status (VPI+) (HR=2.16 P<0.001), and solid/micropapillary-predominant WHO tumour type (SPA/MPPA) (HR=3.29 P<0.001). Crucially, these criteria also identify patient groups benefiting from AC (VI+ HR=0.69 P=0.167, VPI+ HR=0.44 P=0.004, SPA/MPPA HR=0.36 P=0.006). Cases showing VI+/VPI+/SPA/MPPA histology in the absence of AC stage criteria were common (170 of 620 total), and 8 had actually received AC. This group showed much better outcomes than equivalent untreated cases in matched analysis (3-year OS 100.0% vs 31.3%). Inclusion of patients with VI+/VPI+/SPA/MPPA histology would increase AC-eligible patients from 51.0% to 84.0% of non-mucinous tumours in our cohort. CONCLUSIONS: Our data provide preliminary evidence that the consideration of AC in patients with additional high-risk pathological indicators may significantly improve outcomes in operable lung adenocarcinoma, and that AC may be currently underused
Probing Shadowed Nuclear Sea with Massive Gauge Bosons in the Future Heavy-Ion Collisions
The production of the massive bosons and could provide an
excellent tool to study cold nuclear matter effects and the modifications of
nuclear parton distribution functions (nPDFs) relative to parton distribution
functions (PDFs) of a free proton in high energy nuclear reactions at the LHC
as well as in heavy-ion collisions (HIC) with much higher center-of mass
energies available in the future colliders. In this paper we calculate the
rapidity and transverse momentum distributions of the vector boson and their
nuclear modification factors in p+Pb collisions at TeV and in
Pb+Pb collisions at TeV in the framework of perturbative QCD
by utilizing three parametrization sets of nPDFs: EPS09, DSSZ and nCTEQ. It is
found that in heavy-ion collisions at such high colliding energies, both the
rapidity distribution and the transverse momentum spectrum of vector bosons are
considerably suppressed in wide kinematic regions with respect to p+p reactions
due to large nuclear shadowing effect. We demonstrate that in the massive
vector boson productions processes with sea quarks in the initial-state may
give more contributions than those with valence quarks in the initial-state,
therefore in future heavy-ion collisions the isospin effect is less pronounced
and the charge asymmetry of W boson will be reduced significantly as compared
to that at the LHC. Large difference between results with nCTEQ and results
with EPS09 and DSSZ is observed in nuclear modifications of both rapidity and
distributions of and in the future HIC.Comment: 13 pages, 21 figures, version accepted for publication in Eur. Phys.
J.
Determinants of adult vaccination at inner-city health centers: A descriptive study
BACKGROUND: Pneumococcal polysaccharide vaccination rates among adults 65 years and older or less than 65 years with high risk medical conditions are still below Healthy People 2010 recommended levels of 90%. This study was designed to: 1) assess self-reported pneumococcal vaccination rates following health center level interventions to increase adult vaccination rates; and 2) determine factors associated with vaccination. METHODS: Tailored interventions to increase immunizations were implemented at two inner-city health centers. We surveyed 375 patients 50 years of age and older. Multivariate logistic regression examines the predictors of 1) self-reported pneumococcal vaccination and 2) combined self-reported influenza and pneumococcal vaccination. Both of these models were stratified by age group (50–64 years and 65 years and older). RESULTS: Pneumococcal vaccination rates were 45% by self-report, 55% by medical record review, 69% for patients 65 years old and older, 32% for patients 50–64 years; they did not differ by race. Receipt of the previous season's influenza vaccine was significantly related to pneumococcal vaccination among both younger and older patients. Receiving both the pneumococcal vaccine and the most recent influenza vaccine compared with receiving neither, among younger patients was related to unemployment, more frequent physician visits, and belief that those who do not receive the flu shot are more susceptible to the flu. For older patients, receipt of both vaccines was related to nonsmoking status, believing that friends/family think the patient should be vaccinated, seeing posters advertising flu shot clinics, and belief that those who do not receive the flu shot are more susceptible to the flu. CONCLUSION: Our findings suggest that improving overall pneumococcal vaccination rates among eligible adults, has the potential to eliminate racial disparities. Interventions delivering vaccination messages specific to older and younger adult groups may be the best strategy for improving adult vaccination rates
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
In an in vitro model of human tuberculosis, monocyte-microglial networks regulate matrix metalloproteinase-1 and -3 gene expression and secretion via a p38 mitogen activated protein kinase-dependent pathway.
BACKGROUND: Tuberculosis (TB) of the central nervous system (CNS) is characterized by extensive tissue inflammation, driven by molecules that cleave extracellular matrix such as matrix metalloproteinase (MMP)-1 and MMP-3. However, relatively little is known about the regulation of these MMPs in the CNS. METHODS: Using a cellular model of CNS TB, we stimulated a human microglial cell line (CHME3) with conditioned medium from Mycobacterium tuberculosis-infected primary human monocytes (CoMTb). MMP-1 and MMP-3 secretion was detected using ELISAs confirmed with casein zymography or western blotting. Key results of a phospho-array profile that detects a wide range of kinase activity were confirmed with phospho-Western blotting. Chemical inhibition (SB203580) of microglial cells allowed investigation of expression and secretion of MMP-1 and MMP-3. Finally we used promoter reporter assays employing full length and MMP-3 promoter deletion constructs. Student's t-test was used for comparison of continuous variables and multiple intervention experiments were compared by one-way ANOVA with Tukey's correction for multiple pairwise comparisons. RESULTS: CoMTb up-regulated microglial MMP-1 and MMP-3 secretion in a dose- and time-dependent manner. The phospho-array profiling showed that the major increase in kinase activity due to CoMTb stimulation was in p38 mitogen activated protein kinase (MAPK), principally the α and γ subunits. p38 phosphorylation was detected at 15 minutes, with a second peak of activity at 120 minutes. High basal extracellular signal-regulated kinase activity was further increased by CoMTb. Secretion and expression of MMP-1 and MMP-3 were both p38 dependent. CoMTb stimulation of full length and MMP-3 promoter deletion constructs demonstrated up-regulation of activity in the wild type but a suppression site between -2183 and -1612 bp. CONCLUSIONS: Monocyte-microglial network-dependent MMP-1 and MMP-3 gene expression and secretion are dependent upon p38 MAPK in tuberculosis. p38 is therefore a potential target for adjuvant therapy in CNS TB
PGB pair production at LHC and ILC as a probe of the topcolor-assisted technicolor models
The topcolor-assisted technicolor (TC2) model predicts some light pseudo
goldstone bosons (PGBs), which may be accessible at the LHC or ILC. In this
work we study the pair productions of the charged or neutral PGBs at the LHC
and ILC. For the productions at the LHC we consider the processes proceeding
through gluon-gluon fusion and quark-antiquark annihilation, while for the
productions at the ILC we consider both the electron-positron collision and the
photon-photon collision. We find that in a large part of parameter space the
production cross sections at both colliders can be quite large compared with
the low standard model backgrounds. Therefore, in future experiments these
productions may be detectable and allow for probing TC2 model.Comment: 26 pages, 16 figures. slight changes in the text; notations for
curves changed; references adde
Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized FGFR1-3 aberrations. The greatest activity was observed in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (ORR, 25.4%). Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib. Futibatinib demonstrated a manageable safety profile. The most common treatment-emergent adverse events were hyperphosphatemia (81.2%), diarrhea (33.5%), and nausea (30.4%). These results formed the basis for ongoing futibatinib phase II/III trials and demonstrate the potential of genomically selected early-phase trials to help identify molecular subsets likely to benefit from targeted therapy
- …